New York, May 8 (TIWN): Rutgers University has launched a clinical trial to test the safety and efficacy of a new drug that could help prevent serious illness and death in early-stage COVID-19 patients.

The drug is called EDP1815. It is administered orally, and is said to be anti-inflammatory and very safe. It will be given to newly hospitalized COVID-19 patients at Robert Wood Johnson University Hospital.